Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU

Official record

Identifier

NCT07766122

Recruiting locations

country

France

Interventions studied

Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy)

Lead sponsor

University Hospital, Toulouse

Target enrolment

30 participants

Study type

INTERVENTIONAL

Phase

Phase 4

Status

Not yet recruiting

First posted

Aug 14, 2026

Last updated on the registry

Aug 14, 2026

Age

70 Years

Sex

MALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Patient with prostate cancer
* Age ≥ 70 years (HAS 2023)
* Life expectancy \> 5 years
* Clinical stage Clinical stage T1c - T2a PSA \< 20 ng/ml Biopsy :ISUP 2 unilateral on a maximum of 2 contiguous sextants with or without ipsilateral or contralateral focus ISUP1 single focus or multiple foci if only one ISUP 2 focus on targeted biopsy
* Imaging Single lesion PIRADS 3 or 4 or 5 Volume of prostate gland \< 150 ml
* Enrolled in a social security scheme
* Signature of consent

Exclusion Criteria:

* Evidence of extra-prostatic extension or invasion of the seminal vesicles.
* Any condition that, in the judgement of the investigators, would interfere with the subject's ability to
* provide informed consent, comply with study instructions, expose the subject to increased risk, or interfere with the interpretation of study results.
* Patients deprived of their liberty or under legal protection (curatorship and guardianship, safeguard of justice)
* Hypersensitivity to the active substances or to any of the excipients
* Conditions contraindicating magnetic resonance imaging (MRI), such as the presence of internal metallic devices.
* Chronic kidney disease with an eGFR ≤ 60 mL/min
* Liver failure

Indexed under

Prostate Cancer